Guselkumab: Short‐term effectiveness and safety in real clinical practice-Reference-Cited by-同舟云学术

Guselkumab: Short‐term effectiveness and safety in real clinical practice

Published:2020-04-20 Issue:3 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Rodriguez Fernandez‐Freire Lourdes¹,Galán‐Gutierrez Manuel²,Armario‐Hita Jose Carlos³,Perez‐Gil Amalia⁴,Ruiz‐Villaverde Ricardo⁵^ORCID

Affiliation:

1. Dermatology Department Hospital Universitario Virgen del Rocio Sevilla Spain

2. Dermatology Department Hospital Universitario Reina Sofía Córdoba Spain

3. Dermatology Department Hospital Universitario Puerto Real Cádiz Spain

4. Dermatology Department Hospital Universitario Valme Sevilla Spain

5. Dermatology Department Hospital Universitario San Cecilio Granada Spain

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.13344

Reference8 articles.

1. Prevalencia de la psoriasis en España en la era de los agentes biológicos

2. Ficha técnica de brodalumab.Disponible en:https://www.ema.europa.eu/en/documents/product‐information/tremfya‐epar‐product‐information_es.pdf. Acceso: March 14 2020

3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

5. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study;Journal of Clinical Medicine;2024-05-03

2. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G‐EPOSS study;Journal of the European Academy of Dermatology and Venereology;2024-04-11

3. Real‐life data over 36 weeks of guselkumab treatment in psoriasis patients: A single‐center study from Turkey;Journal of Cosmetic Dermatology;2024-03-15

4. Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis;Frontiers in Medicine;2023-12-14

5. Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study;Journal of the European Academy of Dermatology and Venereology;2023-07-18